April 26th 2024
US health officials are growing increasingly worried about rising syphilis cases and have begun creating framework to slow down the spread.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
Moderna’s mRNA RSV Vaccine Shows Positive Results in Phase 3 Trial
January 3rd 2024The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.
Nirsevimab Demonstrates Lasting Efficacy in Infants Through First RSV Season
October 28th 2023The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Malaria Vaccine Recommended by WHO Could Help Fix Supply Issues
October 10th 2023Based on data from an ongoing clinical trial and other studies, the R21 vaccine has been shown to have a high degree of efficacy when administered just before the high transmission season, with data showing a 75% reduction in cases of malaria in the 12 months following the 3-dose series.
Older Women at Greatest Risk of C Diff, COVID-19 Coinfection
September 28th 2023Beyond female gender, comorbidities independently associated with C diff infection in patients diagnosed with COVID-19 included peptic ulcer disease, renal failure, weight loss, diabetes mellitus with complications, and congestive heart failure.